RE: Epilepsy3 Mar 2023 11:58
I hope so too, but their cash situation is a problem. From reading the latest bulletin it looks like we are in for further dilution of up to 20% as the terms of the Mercer CLN deal are changing. CLNs arent great as it is as the market is continuously flooded with more shares and Mercer will control the price, perhaps selling on any spike. This, other than the lack of revenue is the 2nd problem. Perhaps someone with a better knowledge of CLNs who has read the recent report could share their view. We need some serious revenue, and soon, but with all pharma its high risk, high returns if MGC can capitalise on something. Breakthrough epilepsy treatment would be a wonderful thing for sufferers.